Recruiting

Effect of Periodontal Treatment on Metabolic Control in Patients with Type-2 Diabetes Mellitus Treated in the Cardiovascular Healt Program

The objective of this clinical trial is to evaluate the effect of periodontal treatment on the reduction of glycated hemoglobin levels in adult patients with concurrent type 2 diabetes mellitus and periodontitis. Non-surgical periodontal treatment and the application of a quality of life survey will be performed and then controls will be carried out for 1 year.

ClinicalTrials.gov IDNCT06895980

PhaseNA

Enrollment80

SponsorUniversity of Chile

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Periodontitis Chronic Generalized Moderate, Periodontitis, Periodontal Disease, Diabetes Mellitus Type 2

About this study

Interventions

Procedure: Non-surgical periodontal treatment, glycated hemoglobin measurement and application of OHIP-14SP survey. — Non-surgical periodontal treatment will be performed, with periodontal maintenance therapy at 3, 6, 9 and 12 months, with measurement of glycated hemoglobin at each time and application of the OHIP-14SP oral health-related quality of life survey.

Primary outcomes

HbA1c (The glycated hemoglobin) (13 months)

Eligibility information

Inclusion Criteria: * 1a. Patients enrolled in the PSCV with a diagnosis of type 2 diabetes mellitus and who, in turn, have a glycated hemoglobin ≥ 7% (during the last 6 months). * 1b. Patients with a diagnosis of periodontitis (≥ 2 non-adjacent teeth with detectable clinical interproximal attachment loss or, attachment loss ≥ 3mm with depth to probing ≥ 3mm on free faces of ≥ 2 teeth, where the attachment loss was not attributed to non-periodontal causes (Papapanou et al., 2018)). Exclusion Criteria: * 2a. Patients who have received periodontal treatment during the last year. * 2b. Pregnancy/lactation, because they are under treatment under the Explicit Health Guarantee "Oral and Integral Health of Pregnant Women". * 2c. Therapy with antibiotics and/or non-steroidal anti-inflammatory drugs (NSAIDs) in the last 6 months prior to the study.

Study locations

Universidad de Chile, Santiago, Providencia Chile

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.